News related to Acular (Ketorolac Ophthalmic) and/or conditions it is approved for
Progression of age-related macular degeneration in 1 eye then other eye
Source: Eye Health / Blindness News From Medical News Today [2014.10.23]
Having age-related macular degeneration (AMD) in one eye was associated with an increased incidence of AMD and accelerated progression of the debilitating disease in the other eye.
UK data presented at EURETINA 2014 showcase efficacy of EYLEA in clinical practice for the treatment of wet age-related macular degeneration
Source: Eye Health / Blindness News From Medical News Today [2014.10.05]
Bayer HealthCare reports that data have been presented at the 14th EURETINA congress in London, showcasing the efficacy of EYLEA® (aflibercept solution for injection) for the treatment of wet...
Source: MedicineNet Eyeglasses, Sunglasses, and Magnifiers Specialty [2014.01.23]
Title: Macular Degeneration
Category: Diseases and Conditions
Created: 7/23/1999 6:05:00 PM
Last Editorial Review: 1/23/2014 12:00:00 AM
Jetrea Gets FDA Nod for Macular Adhesion
Source: MedPage Today Product Alert [2012.10.19]
WASHINGTON -- The FDA has approved ocriplasmin (Jetrea) as the first nonsurgical treatment for symptomatic vitreomacular adhesion.
'Miniature Telescope' for Eye Approved for Macular Degeneration
Source: MedicineNet Macular Degeneration (Age-Related Type) Specialty [2010.07.07]
Title: 'Miniature Telescope' for Eye Approved for Macular Degeneration
Category: Health News
Created: 7/6/2010 2:10:00 PM
Last Editorial Review: 7/7/2010
How Nigeria prevented an Ebola epidemic
Source: Infectious Diseases / Bacteria / Viruses News From Medical News Today [2014.10.22]
WHO have declared Nigeria free of Ebola virus transmission and describe the country's successful prevention of an unimaginable epidemic as a spectacular story worth telling.
Regeneron's Eylea Works Better vs Avastin and Lucentis in Study
Source: Medscape Ophthalmology Headlines [2014.10.20]
Regeneron Pharmaceuticals said its drug Eylea (aflibercept) for diabetic macular edema produced significantly greater improvement in visual acuity from baseline to 52 weeks compared with Genentech's Avastin (bevacizumab) and Lucentis (ranibizumab).
Reuters Health Information
PodMed: A Medical News Roundup From Johns Hopkins (with audio)
Source: MedPage Today Gastroenterology [2014.10.18]
(MedPage Today) -- This week's topics include fecal transplant capsules, stem cells for macular degeneration, exercise and depression in teens, and Ebola predictions.
Ruboxistaurin (RBX) may reduce risk of vision loss in diabetics
Source: The Doctors Lounge - Endocrinology and Diabetes
Phase III trial demonstrates ruboxistaurin (RBX) may reduce the risk of vision loss especially in diabetic macular edema.